Similar companies
Income Statement (NONE)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 40M | 7% |
| Gross Profit | 15M | 1171% |
| Cost of Revenue | 25M | 16.7% |
| Operating expense | 59M | 86.5% |
| Net Income | -42M | 90.2% |
| EBITDA | -44M | 15.1% |
Balance Sheet (NONE)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 825M | 4.1% |
| Total Liabilities | 764M | 0.7% |
| Total Equity | 61M | 32.9% |
| Shares Outstanding | 300M | 1.1% |
Cash Flow (NONE)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -29M | 33.3% |
| Cash from investing | 25M | 44.1% |
EPS
Financial Highlights for Pacific Biosciences of California in Q2 '25
Pacific Biosciences of California reported a revenue of 40M, which is a 7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 15M, marking a 1171% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 25M, a -16.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 59M, showing a -86.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -42M, showing a 90.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -44M, showing a 15.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Pacific Biosciences of California with growth in revenue, gross profit, and net income.
